This is a working overview of mass spectrometry, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-05-30. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
Identity and purity are established with reversed phase high performance liquid chromatography coupled to mass spectrometry. The chromatographic step separates the target peptide from truncated sequences and deletion products, while the mass measurement confirms the expected molecular weight to within a fraction of a dalton. Because the two common variants differ by the presence of the linker, mass alone can distinguish them in the unconjugated state. Amino acid analysis and peptide mapping are used when sequence level confirmation is required.
Lyophilized material is generally stable for extended periods when held at minus twenty degrees Celsius or below and protected from moisture and light. In solution the peptide is more labile; bond hydrolysis, aggregation and oxidation of susceptible residues all proceed faster at ambient temperature. Repeated freeze and thaw cycles should be avoided because they promote clumping and loss of soluble material. The conjugated variant adds a further consideration, since the maleimide group can hydrolyze in aqueous buffer and lose its ability to react with albumin.
Laboratory handling centers on minimizing exposure to water, heat and oxygen before use. Working solutions are typically prepared in sterile water or a mild buffer, and any residual particulate matter is removed by filtration. When the powder dissolves slowly, a small proportion of acetonitrile or dilute acetic acid is sometimes added as a co-solvent. Containers are kept sealed and desiccated between uses. Records of lot number, reconstitution date and storage conditions support later comparison of results across experiments.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off white powder | Typical lyophilized form |
| Water solubility | Soluble | May need a small organic co-solvent |
| Purity assessment | Chromatographic peak area | Most certificates report a percentage figure |
| Storage temperature | Minus 20 C or lower | Dry, dark, sealed container |
| Identity check | Electrospray mass spectrometry | Compared against theoretical mass |
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
=== National Institute of Standards and Technology === As of 2018 NIST does not provide certificates for the common stable isotope reference materials. As seen at this link showing the light stable isotope references currently available from NIST, this category includes all of the isotopic references critical for isotopic measurement of hydrogen, carbon, oxygen, nitrogen, and sulfur. However, for most of these materials NIST does provide a report of investigation, which gives a reference value that is not certified (following the definitions of May et al. (2000)). For the above examples of USGS34 and USGS35, NIST reports reference values but has not certified the results of Böhlke et al. (2003). Conversely, NIST has not provided a reference value for IAEA-SO-5. As seen at this link, NIST does certify isotopic reference materials for non-traditional "heavy" isotopic systems including rubidium, nickel, strontium, gallium, and thallium, as well as several isotopic systems that would normally be characterized at "light" but non-traditional such as magnesium and chlorine. While the isotopic composition of several of these materials were certified in the mid-1960s, other materials were certified as recently as 2011 (for example, Boric Acid Isotopic Standard 951a).
=== Pharmacokinetics === Carisoprodol has a rapid, 30-minute onset of action, with effects lasting around two to six hours. It is metabolized in the liver via the cytochrome P450 oxidase isozyme CYP2C19, excreted by the kidneys, and has about an eight-hour half-life. In patients with low levels of CYP2C19 (poor metabolizers), standard doses can lead to increased concentrations of carisoprodol (up to a fourfold increase). A considerable proportion of carisoprodol is metabolized to meprobamate, a known addictive substance; this could account for the addictive potential of carisoprodol (meprobamate levels reach higher peak plasma levels than carisoprodol itself following administration). It is slightly water-soluble and freely soluble in ethanol, chloroform and acetone. The drug's solubility is practically independent of pH.
1 May – Brendan Walsh, 50, hurler (Killeagh, Imokilly, Cork senior team). 6 May Derek Keating, 67, politician, TD (2011–2016). Joe Young, 89, Gaelic footballer and hurler (St. Vincent's, Dublin junior team, Galway senior teams). 7 May Seán Keane, 76, fiddler. (The Chieftains). Patrick Joseph McGrath, 77, Roman Catholic prelate, Bishop of San Jose, California (1999–2019). 15 May – Marty Lynch, 59, Gaelic footballer (Newry Mitchels, Newry Bosco, Down senior team). Born in Northern Ireland. 19 May – Seán McCormack, 79, Gaelic footballer (Kilmainhamwood, Meath senior team). 27 May Hugh Callaghan, 93, a member of the Birmingham Six. Graham Knuttel, 69, painter and sculptor. 30 May – Michael Viney, 90, artist, author, journalist and broadcaster. 31 May – Peter Harbison, 84, archaeologist.
Sources: en.wikipedia.org
Metallopeptides (also called metal-peptides or metal peptide complexes) are peptides that contain one or more metal ions in their structure. This specific type of peptide are, just like metalloproteins, metallofoldamers. And very similar to metalloproteins, metallopeptide's functionality is attributed through the contained metal ion cofactor. These short structured peptides are often employed to develop mimics of metalloproteins and systems similar to artificial metalloenzymes. A multitude of naturally occurring peptides display biological and chemical activities when bound to various metal ions. Where different metal ion cofactor can lead to different reactivity and even different folding and physical characteristics (e.g. solubility or stability) of the structure. Synthetic equivalents of such peptides are engineered to bind metal ions and display a variety of physical, chemical, and biological reactivity and characteristics.
== Research == Multiple studies have shown that LDN has promise as a treatment for chronic pain, some autoimmune disorders, and cancers. Studies on the efficacy of LDN for multiple sclerosis have been inconclusive. Clinical trials for its use as treatment of fibromyalgia were initiated in 2021. LDN is also being studied in long COVID. A 2018 therapeutic utilization review concluded that LDN may be an appropriate option for treatment of fibromyalgia and irritable bowel syndrome, but that "proper clinical trials are needed in order to establish evidence that could lead to correct indications, mode of administration, and other aspects necessary for effective clinical pharmacology of [low-dose naltrexone]." The UK's National Health Service echoed this sentiment in 2020. In a 2013 paper published in Arthritis & Rheumatology, authors Jarred Younger and Sean Mackey reported reduced circulating pro‑inflammatory cytokines and self‑reported pain in fibromyalgia patients using LDN. A 2018 review summarized mixed trial outcomes and emphasized methodological limitations. A 2023 systematic review published in the Australian Journal of General Practice found that preliminary research into the use of LDN as a treatment for fibromyalgia is promising. All clinical studies examined showed statistically significant improvements in pain and pain tolerance with mild side effects; however, sample sizes were small and the evidence is inconclusive.
Small-cell carcinoma is an undifferentiated neoplasm composed of primitive-appearing cells. As the name implies, the cells in small-cell carcinomas are smaller than normal cells and barely have room for any cytoplasm. Some researchers identify this as a failure in the mechanism that controls the size of the cells. At the time of diagnosis, 60–70% of people already have metastases.
Sources: en.wikipedia.org
De novo peptide sequencing for mass spectrometry is typically performed without prior knowledge of the amino acid sequence. It is the process of assigning amino acids from peptide fragment masses of a protein. De novo sequencing has proven successful for confirming and expanding upon results from database searches. As de novo sequencing is based on mass and some amino acids have identical masses (e.g. leucine and isoleucine), accurate manual sequencing can be difficult. Therefore, it may be necessary to utilize a sequence homology search application to work in tandem between a database search and de novo sequencing to address this inherent limitation. Database searching has the advantage of quickly identifying sequences, provided they have already been documented in a database. Other inherent limitations of database searching include sequence modifications/mutations (some database searches do not adequately account for alterations to the 'documented' sequence, thus can miss valuable information), the unknown (if a sequence is not documented, it will not be found), false positives, and incomplete and corrupted data. An annotated peptide spectral library can also be used as a reference for protein/peptide identification. It offers the unique strength of reduced search space and increased specificity.
In an absorption refrigeration system, thermal energy is used to drive a refrigerant through an absorber–generator solution circuit rather than relying primarily on a mechanical compressor. Absorption refrigeration has a long history: an ammonia–water machine was introduced by Ferdinand Carré in 1859, and lithium bromide–water systems were introduced for industrial applications in the 1950s. The refrigerant evaporates at low pressure and is absorbed into a liquid absorbent. The resulting solution is pumped to a higher pressure and heated in a generator, which separates refrigerant vapour from the solution. The refrigerant then condenses, expands and returns to the evaporator, while the absorbent solution returns to the absorber. Two important working-fluid pairs are ammonia–water, in which ammonia is the refrigerant and water is the absorbent, and water–lithium bromide, in which water is the refrigerant and lithium bromide is the absorbent. The choice of working pair affects operating pressure, temperature range and system performance. Because absorption systems can be driven by thermal energy, they can use sources such as industrial waste heat that might otherwise be rejected to the environment. Their performance and suitability relative to vapor-compression refrigeration depend on the working pair, cycle configuration, heat-source temperature and operating conditions.
== Colombia == In the late 1980s, major narcotics trafficking and terrorist problems within the region covered by the Southern Command (USSOUTHCOM) worsened. USSOUTHCOM was (and remains) responsible for all of South America, Central America, and the Caribbean (CARIBCOM). The 7th Special Forces Group deployed detachments, trainers and advisers in conjunction with teams from the 1st Psychological Operations Battalion to assist Host Nation (HN) forces. During the late 1990s, 7 SFG(A) also deployed to Colombia and trained three Counter Narcotics Battalions and assisted in the establishment of a Brigade Headquarters. These were the first units of their kind in Colombia and each is known as "Batallón Contra Narcotraficantes" or BACNA. These elements continue to be very successful against the narcotics industry which thrives in Colombia. U.S. Army Special Forces detachments still rotate among various locations within Colombia, training HN units in counter-guerrilla and counter-narcotics roles, and SF detachments routinely deploy to other countries within the USSOUTHCOM area of responsibility.
===== Funding freezes ===== From the outset of 2025, NIH funding operations have faced interruptions on an unprecedented scale under the direction of the current executive branch of the U.S. government; disruptions as of March 2025 include the following: • impeding grants for dementia and ALS research; • hindering procurement of necessary resources, such as those for transporting patient blood samples; • preventing a research scientist from consulting with physicians treating children with a devastating rare condition; • interrupting the supply of mice for genetic studies, with years of research being imperiled as a result; • cutting research grants for training doctoral and postdoctoral students. This has led to protests such as the Bethesda Declaration, an open letter from former and current NIH staffers.
Sources: en.wikipedia.org
The mass difference from the linker is large enough for routine detection by mass spectrometry. The unconjugated form gives a single sharp signal at its expected weight. Material that has already reacted with albumin shows a much higher mass and a broadened chromatographic peak.
Yes. Degradation proceeds faster once the powder is dissolved, especially at room temperature or after multiple freeze and thaw cycles. Working solutions are often aliquoted to avoid repeated handling. Lyophilized powder held cold and dry retains its properties far longer.
Truncated sequences, oxidized residues and aggregated forms can all elute near the main peak. Reversed phase chromatography resolves many of these species, so the number of peaks is a useful indicator of synthesis quality. A single peak does not by itself prove correct sequence, which is why mass confirmation is paired with it.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.